Active Biotech Year-end report January - December 2018
Fourth quarter in brief
- Active Biotech communicated updated information about its financial position
- New data from the LEGATO-HD study presented at the 2018 HSG conference
Other significant events during the January-December period
- Patent regarding tasquinimod for the treatment of multiple myeloma (MM) granted in the US
- The rights issue in April brought the company SEK 47.1 M
- The company's partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago
- The company announced that the Phase II LEGATO-HD trial evaluating the efficacy and safety of laquinimod in Huntington's disease (HD) did not meet its primary endpoint to slow the progression of the disease. However, the secondary endpoint, reduction of brain atrophy, was met. Laquinimod showed excellent safety in the study
- The company is initiating a scientific collaboration with the Wistar Institute in Philadelphia on tasquinimod to support the clinical development in multiple myeloma
- Active Biotech regains global rights to the development and commercialization of laquinimod
- Data from the LEGATO-HD study of laquinimod in Huntington's disease presented at the EHDN meeting
Events after the end of the period
- Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase Ib/II study
- On February 1, 2019, Active Biotech received an indicative, non-binding bid for the company's property, amounting to SEK 275 million, from the real estate company Estea AB. The indicative bid is conditional the due diligence process and Estea securing financing. Active Biotech's Board takes a positive view of the bid
- The US Patent Office (USPTO) approved the patent application regarding tasquinimod for the treatment of acute leukemia in the US
Financial summary
| SEK M | Oct-Dec | Jan-Dec | |||
| 2018 | 2017 | 2018 | 2017 | ||
| Net sales | 4.8 | 5.4 | 20.1 | 20.2 | |
| Operating loss | -7.1 | -58.4 | -29.8 | -102.5 | |
| Loss after tax | -8.9 | -60.1 | -36.9 | -108.8 | |
| Earnings per share (SEK) | -0.06 | -0.49 | -0.27 | -0.89 | |
| Cash and cash equivalents (at close of period) | 25.6 | 25.2 | |||
For further information, please contact:
| Helén Tuvesson, CEO Tel: +46 (0)46 19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46 19 20 00 |
The report is also available at www.activebiotech.com . Active Biotech is obligated to make public the information contained in this interim report pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This information was provided to the media, through the agency of the contact person set out above, for publication on February 14, 2019, at 8:30 a.m. CET.
Attachment
